Trials
1 active
1 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Participants will receive L608 TID over 28 consecutive days.”In the company’s words, NCT07925619 on ClinicalTrials.gov
- Tested for
- Systemic Sclerosis
- Main trialPhase 2
- “This trial is designed to evaluate the efficacy and safety of L608 compared to placebo in patients with SSc-DU.”In the company’s words, NCT07925619 on ClinicalTrials.gov
Other drugs for Systemic Sclerosis
- AnifrolumabAstraZeneca · Phase 3
- AdmilparantBristol Myers Squibb · Phase 3
- BMS-986353Bristol Myers Squibb · Phase 3
- CABA-201Cabaletta Bio · Phase 2/3
- BelimumabGSK · Phase 3
- NerandomilastBoehringer Ingelheim · Phase 3
Coming up1
- 31 Dec 2028Phase 2 trial completes · ClinicalTrials.gov
Changes1
Last 90 days- 9 NovNew trial: none to Phase 2 · ClinicalTrials.gov NCT07925619
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Not yet recruiting | 31 Dec 2028 | Efficacy and Safety Study of L608 in Patients With Systemic Sclerosis-associated Digital Ulcers |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026